Regulus Therapeutics Inc.

RGLS · NASDAQ
Analyze with AI
3/31/2025
12/31/2024
9/30/2024
6/30/2024
Operating Activities
Net Income-$9,634-$12,791-$14,062-$11,036
Dep. & Amort.$85$87-$1,082$89
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,249$2,463$2,422$1,865
Change in WC-$3,113-$1,219$3,357-$1,856
Other Non-Cash-$200-$385-$84-$699
Operating Cash Flow-$10,613-$11,845-$9,449-$11,637
Investing Activities
PP&E Inv.$268$0-$28-$83
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0-$5,328$0
Inv. Sales/Matur.$21,500$24,000$24,000$0
Other Inv. Act.-$268$0$0$0
Investing Cash Flow$21,500$24,000$18,644-$83
Financing Activities
Debt Repay.$0$1,377$0-$551
Stock Issued$45-$93,811$56-$193
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$92,415$0$0
Financing Cash Flow$45$0$56-$744
Forex Effect$0$0$0$0
Net Chg. in Cash$10,932$12,155$9,251-$12,464
Supplemental Information
Beg. Cash$38,590$26,435$17,184$29,648
End Cash$49,522$38,590$26,435$17,184
Free Cash Flow-$10,345-$11,845-$9,477-$11,720
Regulus Therapeutics Inc. (RGLS) Financial Statements & Key Stats | AlphaPilot